NASDAQ:STOK - Stoke Therapeutics Stock Price, Forecast & News

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STOK stock has increased by 6.2% and is now trading at $20.96. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stoke Therapeutics.

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, June 22nd 2020. View our earnings forecast for Stoke Therapeutics.

Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings results on Monday, March, 23rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.21. View Stoke Therapeutics' earnings history.

7 analysts have issued 12 month target prices for Stoke Therapeutics' shares. Their forecasts range from $30.00 to $46.00. On average, they expect Stoke Therapeutics' share price to reach $36.50 in the next year. This suggests a possible upside of 74.1% from the stock's current price. View analysts' price targets for Stoke Therapeutics.

Media stories about STOK stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stoke Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutStoke Therapeutics.

Some companies that are related to Stoke Therapeutics include PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), PPD (SDGR), ArQule (ARQL), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Ra Pharmaceuticals (RARX), Myokardia (MYOK) and Allakos (ALLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Editas Medicine (EDIT), Gilead Sciences (GILD), Gossamer Bio (GOSS), Exxon Mobil (XOM), Akero Therapeutics (AKRO), Alector (ALEC), LogicBio Therapeutics (LOGC), Roku (ROKU), Tesla (TSLA) and Precision BioSciences (DTIL).

(STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STOK stock can currently be purchased for approximately $20.96.

Stoke Therapeutics has a market capitalization of $686.02 million. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe. View additional information about Stoke Therapeutics.

The official website for Stoke Therapeutics is http://www.stoketherapeutics.com/.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]